B-intervention	0	8	Thoracic
I-intervention	9	22	paravertebral
I-intervention	23	28	block
O	29	32	for
O	33	39	breast
O	40	46	cancer
O	47	54	surgery
O	54	55	:
O	56	57	a
O	58	68	randomized
O	69	75	double
O	75	76	-
O	76	81	blind
O	82	87	study
O	87	88	.

O	89	91	We
O	92	100	examined
O	101	103	in
O	104	108	this
O	109	119	randomized
O	119	120	,
O	121	127	double
O	127	128	-
O	128	133	blind
O	134	139	study
O	140	147	whether
O	148	149	a
O	150	160	multilevel
O	161	174	paravertebral
O	175	180	block
O	181	190	performed
O	191	197	before
O	198	205	general
O	206	216	anesthesia
O	217	221	with
O	222	230	propofol
O	231	234	and
O	235	236	a
O	237	246	laryngeal
O	247	251	mask
O	252	260	enhances
O	261	274	postoperative
O	275	284	analgesia
O	285	290	after
O	291	297	breast
O	298	304	cancer
O	305	312	surgery
O	312	313	.

B-total-participants	314	320	Eighty
I-total-participants	320	321	-
I-total-participants	321	326	eight
O	327	335	patients
O	336	340	were
O	341	351	randomized
O	352	354	to
O	355	362	receive
O	363	376	paravertebral
O	377	387	injections
O	388	392	with
O	393	399	either
O	400	411	ropivacaine
O	412	413	0
O	413	414	.
O	414	415	5
O	415	416	%
O	417	418	(
O	418	420	30
O	421	423	mL
O	423	424	)
O	425	427	or
O	428	430	an
O	431	441	equivalent
O	442	448	amount
O	449	451	of
B-control	452	460	isotonic
I-control	461	467	saline
O	467	468	.

O	469	473	Nine
O	474	482	patients
O	483	487	were
O	488	496	excluded
O	497	502	after
O	503	516	randomization
O	516	517	,
O	518	522	thus
B-total-participants	523	525	79
O	526	534	patients
O	535	543	remained
O	544	547	for
O	548	558	evaluation
O	559	560	(
O	560	571	ropivacaine
O	571	572	,
O	573	574	n
O	575	576	=
B-intervention-participants	577	579	38
O	579	580	;
O	581	588	placebo
O	588	589	,
O	590	591	n
O	592	593	=
B-control-participants	594	596	41
O	596	597	)
O	597	598	.

O	599	608	Variables
O	609	611	of
O	612	620	efficacy
O	621	625	were
O	626	629	the
O	630	636	amount
O	637	639	of
O	640	648	fentanyl
O	649	658	delivered
O	659	661	by
O	662	665	the
O	666	673	patient
O	673	674	-
O	674	684	controlled
O	685	694	analgesia
O	695	701	device
O	702	704	in
O	705	708	the
O	709	723	postanesthesia
O	724	728	care
O	729	733	unit
O	734	735	(
O	735	739	PACU
O	739	740	)
O	740	741	,
O	742	755	postoperative
O	756	760	pain
O	761	769	measured
O	770	772	on
O	773	774	a
O	775	782	numeric
O	783	789	rating
O	790	795	scale
O	796	798	at
O	799	806	regular
O	807	816	intervals
O	817	821	from
O	822	825	the
O	826	829	day
O	830	832	of
O	833	840	surgery
O	841	844	and
O	845	850	until
O	851	854	the
O	855	861	second
O	862	875	postoperative
O	876	879	day
O	879	880	.

O	881	884	The
B-outcome	885	891	median
I-outcome	892	903	consumption
I-outcome	904	906	of
I-outcome	907	915	fentanyl
I-outcome	916	918	in
I-outcome	919	922	the
I-outcome	923	927	PACU
O	928	931	was
O	932	936	less
O	937	939	in
O	940	943	the
O	944	955	ropivacaine
O	956	961	group
O	962	970	compared
O	971	975	with
O	976	979	the
O	980	987	placebo
O	988	993	group
O	994	995	(
B-iv-cont-median	995	996	0
I-iv-cont-median	997	1003	microg
O	1004	1005	[
O	1005	1010	range
O	1010	1011	:
O	1012	1013	0
O	1013	1014	-
O	1014	1017	250
O	1018	1024	microg
O	1024	1025	]
O	1026	1032	versus
B-cv-cont-median	1033	1036	100
I-cv-cont-median	1037	1043	microg
O	1044	1045	[
O	1045	1050	range
O	1050	1051	:
O	1052	1053	0
O	1053	1054	-
O	1054	1057	800
O	1058	1064	microg
O	1064	1065	]
O	1065	1066	,
O	1067	1068	P
O	1069	1070	=
O	1071	1072	0
O	1072	1073	.
O	1073	1076	001
O	1076	1077	)
O	1077	1078	.

O	1079	1083	Also
O	1083	1084	,
O	1085	1090	fewer
O	1091	1099	patients
O	1100	1102	in
O	1103	1106	the
O	1107	1118	ropivacaine
O	1119	1124	group
O	1125	1133	reported
B-outcome	1134	1138	pain
I-outcome	1139	1140	>
I-outcome	1141	1143	or
I-outcome	1144	1145	=
I-outcome	1145	1146	3
O	1147	1149	on
O	1150	1153	the
O	1154	1161	numbers
O	1162	1168	rating
O	1169	1174	scale
O	1175	1177	in
O	1178	1181	the
O	1182	1186	PACU
O	1187	1188	(
B-iv-bin-abs	1188	1190	13
O	1191	1193	vs
B-cv-bin-abs	1194	1196	31
O	1196	1197	,
O	1198	1199	P
O	1200	1201	<
O	1202	1203	0
O	1203	1204	.
O	1204	1208	0001
O	1208	1209	)
O	1209	1210	.

O	1211	1213	No
O	1214	1225	statistical
O	1226	1236	difference
O	1237	1239	in
B-outcome	1240	1244	pain
I-outcome	1245	1251	scores
O	1252	1254	or
B-outcome	1255	1266	consumption
I-outcome	1267	1269	of
I-outcome	1270	1280	analgesics
O	1281	1286	could
O	1287	1289	be
O	1290	1302	demonstrated
O	1303	1308	after
O	1309	1318	discharge
O	1319	1323	from
O	1324	1327	the
O	1328	1332	PACU
O	1332	1333	.

O	1334	1335	A
O	1336	1346	multilevel
O	1347	1360	paravertebral
O	1361	1366	block
O	1367	1375	provides
O	1376	1380	good
O	1381	1390	analgesia
O	1391	1394	for
O	1395	1401	breast
O	1402	1409	surgery
O	1409	1410	,
O	1411	1414	but
O	1415	1418	the
O	1419	1427	duration
O	1428	1430	of
O	1431	1440	analgesia
O	1441	1443	is
O	1444	1451	briefer
O	1452	1456	than
O	1457	1466	described
O	1467	1469	in
O	1470	1478	previous
O	1479	1486	studies
O	1486	1487	.
